Search

Your search keyword '"Authier, François-Jérôme"' showing total 330 results
Start Over Author "Authier, François-Jérôme"
330 results on '"Authier, François-Jérôme"'

1. Loss of phospholipase PLAAT3 causes a mixed lipodystrophic and neurological syndrome due to impaired PPARγ signaling

Author

Schuermans, Nika, El Chehadeh, Salima, Hemelsoet, Dimitri, Gautheron, Jérémie, Vantyghem, Marie-Christine, Nouioua, Sonia, Tazir, Meriem, Vigouroux, Corinne, Auclair, Martine, Bogaert, Elke, Dufour, Sara, Okawa, Fumiya, Hilbert, Pascale, Van Doninck, Nike, Taquet, Marie-Caroline, Rosseel, Toon, De Clercq, Griet, Debackere, Elke, Van Haverbeke, Carole, Cherif, Ferroudja Ramdane, Urtizberea, Jon Andoni, Chanson, Jean-Baptiste, Funalot, Benoit, Authier, François-Jérôme, Kaya, Sabine, Terryn, Wim, Callens, Steven, Depypere, Bernard, Van Dorpe, Jo, Poppe, Bruce, Impens, Francis, Mizushima, Noboru, Depienne, Christel, Jéru, Isabelle, and Dermaut, Bart

Published
2023
Full Text
View/download PDF

2. Clinical and functional characterization of a long survivor congenital titinopathy patient with a novel metatranscript-only titin variant

Author

Cardone, Nastasia, Moula, Melissa, Baelde, Rianne J., Biquand, Ariane, Villanova, Marcello, Metay, Corinne, Fiorillo, Chiara, Baratto, Serena, Merlini, Luciano, Sabatelli, Patrizia, Romero, Norma B., Relaix, Frederic, Authier, François Jérôme, Taglietti, Valentina, Savarese, Marco, de Winter, Josine, Ottenheijm, Coen, Richard, Isabelle, and Malfatti, Edoardo

Published
2023
Full Text
View/download PDF

3. An up-to-date myopathologic characterisation of facioscapulohumeral muscular dystrophy type 1 muscle biopsies shows sarcolemmal complement membrane attack complex deposits and increased skeletal muscle regeneration

Author

Hubregtse, Lisanne, Bouman, Karlijn, Lama, Chéryane, Lassche, Saskia, de Graaf, Nicolas, Taglietti, Valentina, Küsters, Benno, Periou, Baptiste, Relaix, Frédéric, van Engelen, Baziel, Authier, François-Jerôme, Voermans, Nicol C., and Malfatti, Edoardo

Published
2024
Full Text
View/download PDF

5. Changes in amyloidosis phenotype over 11 years in a cardiac amyloidosis referral centre cohort in France

Author

Damy, Thibaud, Zaroui, Amira, de Tournemire, Marie, Kharoubi, Mounira, Gounot, Romain, Galat, Arnault, Guendouz, Soulef, Funalot, Benoit, Itti, Emmanuel, Roulin, Louise, Audard, Vincent, Fanen, Pascale, Leroy, Vincent, Poulot, Elsa, Belhadj, Karim, Mallet, Sophie, Deep Singh Chadah, Gagan, Planté-Bordeneuve, Violaine, Gendre, Thierry, Chevalier, Xavier, Guignard, Sandra, Bequignon, Emilie, Bartier, Sophie, Folliguet, Thierry, Lemonier, François, Audureau, Etienne, Tixier, Denis, Canoui-Poitrine, Florence, Lefaucheur, Jean-Pascal, Souvannanorath, Sarah, Authier, Francois-Jerome, Maupou, Steven, Hittinger, Luc, Molinier-Frenkel, Valérie, David, Jean-Philippe, Broussier, Amaury, Oghina, Silvia, and Teiger, Emmanuel

Published
2023
Full Text
View/download PDF

9. Widespread Myalgia and Chronic Fatigue: Phagocytes from Macrophagic Myofasciitis Patients Exposed to Aluminum Oxyhydroxide-Adjuvanted Vaccine Exhibit Specific Inflammatory, Autophagic, and Mitochondrial Responses.

Author

Masson, Jean-Daniel, Badran, Ghidaa, Gherardi, Romain K., Authier, François-Jérôme, and Crépeaux, Guillemette

Subjects
CHRONIC fatigue syndrome, FATIGUE (Physiology), IMMUNE system, MYALGIA, PHAGOCYTES
Abstract

(1) Background: Macrophagic myofasciitis (MMF) is an inflammatory histopathological lesion demonstrating long-term biopersistence of vaccine-derived aluminum adjuvants within muscular phagocytic cells. Affected patients suffer from widespread myalgia and severe fatigue consistent with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), a poorly understood disorder suspected to result from chronic immune stimulation by infectious and inorganic particles. (2) Methods: In this study we determined the immuno-metabolic properties of MMF phagocytic cells compared to controls, at rest and upon exposure to aluminum oxyhydroxide adjuvant, with or without adsorbed antigens, using protein quantification and an oxygen consumption assay. (3) Results: MMF and control cells similarly internalized the adjuvant and vaccine but MMF cells specifically expressed Rubicon and Nox2, two molecules unique to the LC3-associated phagocytosis (LAP) machinery, a non-canonical autophagic pathway able to downregulate canonical autophagy. MMF cells exhibited an altered inflammatory secretome, producing more pain-inducing CXC chemokines and less TNF-α than controls, consistent with chronic myalgia and exhaustion of the immune system previously documented in ME/CFS. MMF cells exhibited mitochondrial metabolism dysfunction, with exacerbated reaction to adjuvanted vaccine, contrasting with limited spare respiratory capacity and marked proton leak weakening energy production. (4) Conclusions: MMF phagocytes seemingly use LAP to handle aluminum oxyhydroxide vaccine particles, secrete pain-inducing molecules, and exhibit exacerbated metabolic reaction to the vaccine with limited capacity to respond to ongoing energetic requests. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Characterizing Acute-Onset Small Fiber Neuropathy

Author

Gendre, Thierry, primary, Lefaucheur, Jean-Pascal, additional, Nordine, Tarik, additional, Baba-Amer, Yasmine, additional, Authier, François-Jérôme, additional, Devaux, Jérôme, additional, and Créange, Alain, additional

Published
2024
Full Text
View/download PDF

11. Receptor interacting protein kinase‐3 mediates both myopathy and cardiomyopathy in preclinical animal models of Duchenne muscular dystrophy

Author

Bencze, Maximilien, primary, Periou, Baptiste, additional, Punzón, Isabel, additional, Barthélémy, Inès, additional, Taglietti, Valentina, additional, Hou, Cyrielle, additional, Zaidan, Louai, additional, Kefi, Kaouthar, additional, Blot, Stéphane, additional, Agbulut, Onnik, additional, Gervais, Marianne, additional, Derumeaux, Geneviève, additional, Authier, François‐Jérôme, additional, Tiret, Laurent, additional, and Relaix, Fréderic, additional

Published
2023
Full Text
View/download PDF

13. A recurrent RYR1 mutation associated with early-onset hypotonia and benign disease course

Author

Biancalana, Valérie, Rendu, John, Chaussenot, Annabelle, Mecili, Helen, Bieth, Eric, Fradin, Mélanie, Mercier, Sandra, Michaud, Maud, Nougues, Marie-Christine, Pasquier, Laurent, Sacconi, Sabrina, Romero, Norma B., Marcorelles, Pascale, Authier, François Jérôme, Gelot Bernabe, Antoinette, Uro-Coste, Emmanuelle, Cances, Claude, Isidor, Bertrand, Magot, Armelle, Minot-Myhie, Marie-Christine, Péréon, Yann, Perrier-Boeswillwald, Julie, Bretaudeau, Gilles, Dondaine, Nicolas, Bouzenard, Alison, Pizzimenti, Mégane, Eymard, Bruno, Ferreiro, Ana, Laporte, Jocelyn, Fauré, Julien, and Böhm, Johann

Published
2021
Full Text
View/download PDF

16. Hemifacial myohyperplasia is due to somatic muscular PIK3CA gain-of-function mutations and responds to pharmacological inhibition

Author

Bayard, Charles, primary, Segna, Eleonora, additional, Taverne, Maxime, additional, Fraissenon, Antoine, additional, Hennocq, Quentin, additional, Periou, Baptiste, additional, Zerbib, Lola, additional, Ladraa, Sophia, additional, Chapelle, Célia, additional, Hoguin, Clément, additional, Kaltenbach, Sophie, additional, Villarese, Patrick, additional, Asnafi, Vahid, additional, Broissand, Christine, additional, Nemazanyy, Ivan, additional, Autret, Gwennhael, additional, Goudin, Nicolas, additional, Legendre, Christophe, additional, Authier, François-Jérôme, additional, Viel, Thomas, additional, Tavitian, Bertrand, additional, Gitiaux, Cyril, additional, Fraitag, Sylvie, additional, Duong, Jean-Paul, additional, Delcros, Clarisse, additional, Sergent, Bernard, additional, Picard, Arnaud, additional, Dussiot, Michael, additional, Guibaud, Laurent, additional, Khonsari, Roman, additional, and Canaud, Guillaume, additional

Published
2023
Full Text
View/download PDF

22. Thyroid-stimulating hormone receptor signaling restores skeletal muscle stem cell regeneration in rats with muscular dystrophy

Author

Taglietti, Valentina, primary, Kefi, Kaouthar, additional, Rivera, Lea, additional, Bergiers, Oriane, additional, Cardone, Nastasia, additional, Coulpier, Fanny, additional, Gioftsidi, Stamatia, additional, Drayton-Libotte, Bernadette, additional, Hou, Cyrielle, additional, Authier, François-Jérôme, additional, Pietri-Rouxel, France, additional, Robert, Matthieu, additional, Bremond-Gignac, Dominique, additional, Bruno, Claudio, additional, Fiorillo, Chiara, additional, Malfatti, Edoardo, additional, Lafuste, Peggy, additional, Tiret, Laurent, additional, and Relaix, Frédéric, additional

Published
2023
Full Text
View/download PDF

25. Revisiting idiopathic eosinophilic myositis: towards a clinical-pathological continuum from the muscle to the fascia and skin

Author

Fermon, Cécile, primary, Lessard, Lola E R, additional, Fenouil, Tanguy, additional, Meyer, Alain, additional, Faruch-Bilfeld, Marie, additional, Robert, Marie, additional, Landel, Verena, additional, Hot, Arnaud, additional, Authier, François-Jérôme, additional, Streichenberger, Nathalie, additional, and Gallay, Laure, additional

Published
2022
Full Text
View/download PDF

26. Obesity impairs skeletal muscle repair through NID-1 mediated extracellular matrix remodeling by mesenchymal progenitors

Author

Pérez-Díaz, Sergio, primary, Koumaiha, Zeynab, additional, Borok, Matthew Jay, additional, Aurade, Frederic, additional, Pini, Maria, additional, Periou, Baptiste, additional, Rouault, Christine, additional, Baba-Amer, Yasmine, additional, Clément, Karine, additional, Derumeaux, Genevieve, additional, Authier, François Jérôme, additional, Lafuste, Peggy, additional, and Relaix, Frederic, additional

Published
2022
Full Text
View/download PDF

29. Revisiting idiopathic eosinophilic myositis: towards a clinical-pathological continuum from the muscle to the fascia and skin.

Author

Fermon, Cécile, Lessard, Lola E R, Fenouil, Tanguy, Meyer, Alain, Faruch-Bilfeld, Marie, Robert, Marie, Landel, Verena, Hot, Arnaud, Authier, François-Jérôme, Streichenberger, Nathalie, and Gallay, Laure

Subjects
RESEARCH, SKELETAL muscle, BIOPSY, SKIN, FASCIAE (Anatomy), RETROSPECTIVE studies, CASE studies, DESCRIPTIVE statistics, RESEARCH funding, EOSINOPHILIA-myalgia syndrome
Abstract

Objectives Idiopathic inflammatory myopathies are mainly defined by inflammatory infiltrates within the muscle (lymphocytes and macrophages). Eosinophil muscle infiltration has been described in idiopathic eosinophilic myositis (IEM) and rarely in EF. This study aimed to further delineate the nosological frame of idiopathic eosinophil muscle infiltration through the exhaustive analysis of IEM and EF patients. Methods This multicentre retrospective case series included IEM patients diagnosed between 2000 and 2022. IEM inclusion criteria were eosinophilic muscle infiltration with myositis pathological features, after the exclusion of differential diagnoses. An additional group of EF patients diagnosed between 2016 and 2022 was constituted. Inclusion criteria were an EF diagnosis and fascia thickening with inflammatory infiltrate. Results A total of 20 IEM cases and 10 EF cases were included. The median (interquartile range) age at diagnosis was 65 (49–70) years; there were 18 males. Data analysis delineated four subgroups: focal EM (FEM, n  = 3), diffuse EM (DEM, n  = 6), eosinophilic myofasciitis (EMF, n  = 11) and EF (n  = 10). FEM represented a limited and benign form of myositis. DEM cases presented objective muscle impairment with eosinophilic muscle infiltration. EMF patients presented subjective muscle impairment (myalgia, 55%), fasciitis (on histology and/or imaging), eosinophilic muscle infiltration and frequent hypereosinophilia (55%). EF patients presented myalgia (50%), muscle lesions on histology with fascia-restricted inflammatory infiltrates with (60%) or without (40%) eosinophils. Conclusions The analysis of IEM and EF patient characteristics delineates four subgroups (FEM, DEM, EMF and EF) in terms of clinical, laboratory, imaging, pathological and outcome specificities, and proposes an adapted diagnostic and care management approach. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

35. Additional file 1 of Duchenne muscular dystrophy trajectory in R-DMDdel52 preclinical rat model identifies COMP as biomarker of fibrosis

Author

Taglietti, Valentina, Kefi, Kaouthar, Bronisz-Budzyńska, Iwona, Mirciloglu, Busra, Rodrigues, Mathilde, Cardone, Nastasia, Coulpier, Fanny, Periou, Baptiste, Gentil, Christel, Goddard, Melissa, Authier, François-Jérôme, Pietri-Rouxel, France, Malfatti, Edoardo, Lafuste, Peggy, Tiret, Laurent, and Relaix, Frederic

Subjects
musculoskeletal system
Abstract

Additional file 1. Fig. S1 Myofibre CSA of the diaphragm and morphological evaluation of TA muscle. Fig. S2 Inflammatory cytokine evaluation and fibre type switching in R-DMDdel52 rats. Fig. S3 COMP expression in heart and diaphragm

Published
2022
Full Text
View/download PDF

36. Efficacy and tolerance of corticosteroids and methotrexate in patients with juvenile dermatomyositis: a retrospective cohort study

Author

Rodero, Mathieu P, Dabbak, Imène, Rodero, Mathieu, Aeschlimann, Florence, Authier, François-Jérôme, Bodemer, Christine, Quartier, Pierre, Bondet, Vincent, Charuel, Jean-Luc, Duffy, Darragh, Gitiaux, Cyril, Bader-Meunier, Brigitte, Service d'immuno-hématologie pédiatrique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de référence des rhumatismes inflammatoires et maladies autoimmunes systémiques rares de l'enfant [Paris] (RAISE), AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Chimie et Biologie, Modélisation et Immunologie pour la Thérapie (CBMIT), Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques (LCBPT - UMR 8601), Université Paris Descartes - Paris 5 (UPD5)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Centre de Référence National des Maladies Génétiques à Expression Cutanée (MAGEC), Service de Dermatologie, CHU Necker - Enfants Malades [AP-HP], Immunologie Translationnelle - Translational Immunology lab, Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Université Paris Cité (UPCité), Centre d'investigation clinique Paris Est [CHU Pitié Salpêtrière] (CIC Paris-Est), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Funding: This work was supported by a research grant from Association Française contre les Myopathies (AFM) via TRANSLAMUSCLE (PROJECT 19507) and a research grant from Agence Nationale de la Recherche (ANR) via project JDMINF2 (ANR-21-CE17-0025)., ANR-21-CE17-0025,JDMINF2,Dérégulation de la voie de l'interféron de type I dans la dermatomyosite juvénile: mieux comprendre la physiopathologie pour mieux identifier de nouveaux biomarqueurs pronostiques(2021), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Centre National de la Recherche Scientifique (CNRS), Institut Pasteur [Paris]-Université Paris Cité (UPCité), Unité de Recherche Clinique des hôpitaux Pitié-Salpêtrière – Charles Foix [CHU Pitié Salpêtrière] (URC PSL-CFX), CHU Charles Foix [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Direction de la Recherche Clinique et de l'Innovation [AP-HP] (DRCI), Hôpital Henri Mondor, This work was supported by a research grant from Association Française contre les Myopathies (AFM) via TRANSLAMUSCLE (PROJECT 19507) and a research grant from Agence Nationale de la Recherche (ANR) via project JDMINF2 (ANR-21-CE17-0025)., Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPC), Immunobiologie des Cellules dendritiques, Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Direction de la Recherche Clinique et de l'Innovation [AP-HP] (DRCI)

Subjects
Myositis, juvenile dermatomyositis, [SDV]Life Sciences [q-bio], Dermatomyositis, methotrexate, paediatric rheumatology, Muscular Diseases, Rheumatology, Adrenal Cortex Hormones, Humans, [SDV.IMM]Life Sciences [q-bio]/Immunology, Pharmacology (medical), Child, Retrospective Studies
Abstract

Objectives To assess the efficacy and tolerance of the conventional first-line treatment by MTX and CS in patients with JDM regardless of severity. Methods We conducted a monocentric retrospective study of patients with newly diagnosed JDM treated with MTX and CS from 2012 to 2020. The proportion of clinically inactive disease (CID) within 6 months of MTX initiation was evaluated using both Paediatric Rheumatology International Trials Organisation (PRINTO) criteria (evaluating muscle inactive disease) and DAS (evaluating skin inactive disease). We compared responders and non-responders using univariate analyses. Results Forty-five patients with JDM, out of which 30 (67%) severe JDM, were included. After 6 months of treatment with MTX and CS, complete CID, muscle CID and skin CID were achieved in 14/45 (31%), 19/45 (42%) and 15/45 (33%) patients, respectively. The absence of myositis-specific (MSA) or myositis-associated autoantibodies (MAA) at diagnosis was associated with a better overall, cutaneous and muscular therapeutic response, compared with antibody-positive forms (P Conclusions Conventional first-line treatment with MTX was not efficient in a large subset of JDM patients, especially in patients with MSA-positive forms, and in patients with severe JDM. Larger, multicentre cohorts are required to confirm these data and to identify new predictive biomarkers of MTX response, in order to treat patients with JDM as early as possible with appropriate targeted drugs.

Published
2022

37. Comparative study between cognitive phenotypes of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Multiple Sclerosis

Author

Aoun Sebaiti, Mehdi, Gounden, Yannick, Samson, C., Wahab, A., Créange, A, Hainselin, Mathieu, Authier, François-Jérôme, and Hainselin, Mathieu

Subjects
[SHS.PSY] Humanities and Social Sciences/Psychology, [SHS.EDU] Humanities and Social Sciences/Education, [SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [SDV.NEU.PC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [SDV.NEU.SC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences
Published
2022

39. Systemic light chain amyloidosis myopathy responsive to daratumumab monotherapy.

Author

Chitimus, Diana Maria, Berling, Edouard, Garderet, Laurent, Venturelli, Nadia, Malfatti, Edoardo, Authier, François Jérôme, Nicolas, Guillaume, Laforêt, Pascal, and Lefeuvre, Claire

Subjects
DARATUMUMAB, CARDIAC amyloidosis, AMYLOIDOSIS, MUSCLE diseases, MUSCLE weakness, AMYLOID plaque
Abstract

Background and purpose: Amyloid myopathy is a rare and severe manifestation of systemic light chain (AL) amyloidosis. Early diagnosis and staging are mandatory for optimal therapy, given the rapid progression of muscle weakness. Despite the efficacy of bortezomib‐based treatment regimens, there is a lack of therapeutic alternatives in non‐responsive patients. Method: The case report of a patient with systemic AL amyloidosis myopathy treated with daratumumab is presented. Results: A 70‐year‐old man displayed severe proximal muscle weakness which had developed over a 10‐month period. Blood tests revealed an immunoglobulin A lambda monoclonal gammopathy, whilst muscle biopsy showed amyloid deposits within the arteriolar walls, confirming the diagnosis of amyloid myopathy associated with AL amyloidosis. Initial treatment with a bortezomib‐based regimen showed no clinical or hematological improvement. After switching to daratumumab monotherapy, our patient achieved a favorable evolution with respect to functional muscle scoring and a complete hematological response. Conclusion: To our knowledge, this is the first case report of an amyloid myopathy showing a remarkable clinical improvement in response to daratumumab monotherapy. It thereby highlights the potential of daratumumab as a monotherapeutical approach to the treatment of amyloid myopathy complicating AL amyloidosis. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

40. Efficacy and tolerance of corticosteroids and methotrexate in patients with juvenile dermatomyositis: a retrospective cohort study

Author

Dabbak, Imène, primary, Rodero, Mathieu P, additional, Aeschlimann, Florence A, additional, Authier, François-Jérôme, additional, Bodemer, Christine, additional, Quartier, Pierre, additional, Bondet, Vincent, additional, Charuel, Jean-Luc, additional, Duffy, Darragh, additional, Gitiaux, Cyril, additional, and Bader-Meunier, Brigitte, additional

Published
2022
Full Text
View/download PDF

42. Receptor interacting protein kinase-3 mediates both myopathy and cardiomyopathy in preclinical animal models of Duchenne muscular dystrophy

Author

Bencze, Maximilien, primary, Periou, Baptiste, additional, Punzón, Isabel, additional, Barthélémy, Inès, additional, Taglietti, Valentina, additional, Hou, Cyrielle, additional, Zaidan, Louai, additional, Kefi, Kaouthar, additional, Blot, Stéphane, additional, Agbulut, Onnik, additional, Gervais, Marianne, additional, Derumeaux, Geneviève, additional, Tiret, Laurent, additional, Authier, François-Jérôme, additional, and Relaix, Fréderic, additional

Published
2022
Full Text
View/download PDF

46. Nonsystemic vasculitic neuropathy: Presentation and long-term outcome from a French cohort of 50 patients

Author

Quirins, Marion, primary, Théaudin, Marie, additional, Cohen-Aubart, Fleur, additional, Créange, Alain, additional, Mouthon, Luc, additional, Genty, Solène, additional, Kahn, Jean-Emmanuel, additional, Bérezné, Alice, additional, Rigolet, Aude, additional, Adams, David, additional, Adam, Clovis, additional, Amoura, Zahir, additional, Benveniste, Olivier, additional, Authier, François-Jérôme, additional, Guillevin, Loïc, additional, Maisonobe, Thierry, additional, and Terrier, Benjamin, additional

Published
2021
Full Text
View/download PDF

50. European Network on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (EUROMENE) : Expert Consensus on the Diagnosis, Service Provision, and Care of People with ME/CFS in Europe

Author

Nacul, Luis, Authier, François Jérôme, Scheibenbogen, Carmen, Lorusso, Lorenzo, Helland, Ingrid Bergliot, Martin, Jose Alegre, Sirbu, Carmen Adella, Mengshoel, Anne Marit, Polo, Olli, Behrends, Uta, Nielsen, Henrik, Grabowski, Patricia, Sekulic, Slobodan, Sepulveda, Nuno, Estévez-López, Fernando, Zalewski, Paweł, Pheby, Derek, Castro-Marrero, Jesús, Sakkas, Giorgos K., Capelli, Enrica, Brundsdlund, Ivan, Cullinan, John, Krumina, Angelika, Bergquist, Jonas, Murovska, Modra, Vermuelen, Ruud C. W., Lacerda, Eliana, Universitat Autònoma de Barcelona, Child and Adolescent Psychiatry / Psychology, Institut Català de la Salut, [Nacul L] London School of Hygiene and Tropical Medicine, Faculty of Infectious and Tropical Diseases, London WC1E 7HT, UK. BC Women’s Hospital, Vancouver, BC V6H 3N1, Canada. [Authier FJ] Faculty of Medicine Créteil—Paris Est, 94010 Creteil, France. [Scheibenbogen C] Institute of Medical Immunology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany. [Lorusso L] Neurology and Stroke Unit—Neuroscience Department—A.S.S.T.—Lecco, 23900 Merate, Italy. [Helland IB] National Advisory Unit on CFS/ME, Oslo University Hospital, Rikshospitalet OUS, 0372 Oslo, Norway. [Martin JA] Unitat de Fatiga Crònica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Castro-Marrero J] Secció de Reumatologia, Unitat de Recerca en Síndrome de Fatiga Crònica / Encefalomielitis Miàlgica (SFC/EM), Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Chronic Fatigue Syndrome, Medicine (General), diagnosis, Service provision, Encephalomyelitis, Care, Malalties - Presa de decisions, Health services, 0302 clinical medicine, Health care, Diagnosis, Other subheadings::/diagnosis [Other subheadings], 030212 general & internal medicine, health care economics and organizations, Fatigue Syndrome, Chronic, General Medicine, Psychological Phenomena::Mental Processes::Thinking::Decision Making::Consensus [PSYCHIATRY AND PSYCHOLOGY], ddc, Europe, Nervous System Diseases::Central Nervous System Diseases::Encephalomyelitis::Nervous System Diseases::Fatigue Syndrome, Chronic [DISEASES], localizaciones geográficas::Europa (continente) [DENOMINACIONES GEOGRÁFICAS], fenómenos psicológicos::procesos mentales::pensamiento::toma de decisión::consenso [PSIQUIATRÍA Y PSICOLOGÍA], Myalgic Encephalomyelitis, Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi, musculoskeletal diseases, medicine.medical_specialty, Opinion, Consensus, Otros calificadores::/diagnóstico [Otros calificadores], Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Geographic Locations::Europe [GEOGRAPHICALS], Síndrome de fatiga crònica - Diagnòstic - Europa, 03 medical and health sciences, R5-920, medicine, Chronic fatigue syndrome, Humans, care, health services, enfermedades del sistema nervioso::enfermedades del sistema nervioso central::encefalomielitis::enfermedades del sistema nervioso::síndrome de fatiga crónica [ENFERMEDADES], business.industry, Network on, Expert consensus, Health Care Service and Management, Health Policy and Services and Health Economy, medicine.disease, Family medicine, Clinical diagnosis, business, Delivery of Health Care, 030217 neurology & neurosurgery
Abstract

Encefalomielitis miàlgica/síndrome de fatiga crònica; Cura; Diagnòstic Myalgic encephalomyelitis/chronic fatigue syndrome; Care; Diagnosis Encefalomielitis miálgica/síndrome de fatiga crónica; Cuidado; Diagnóstico Designed by a group of ME/CFS researchers and health professionals, the European Network on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (EUROMENE) has received funding from the European Cooperation in Science and Technology (COST)—COST action 15111—from 2016 to 2020. The main goal of the Cost Action was to assess the existing knowledge and experience on health care delivery for people with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in European countries, and to enhance coordinated research and health care provision in this field. We report our findings and make recommendations for clinical diagnosis, health services and care for people with ME/CFS in Europe, as prepared by the group of clinicians and researchers from 22 countries and 55 European health professionals and researchers, who have been informed by people with ME/CFS. This research received no external funding. EUROMENE receives funding for networking activities from the COST programme (COST Action 15111), via the COST Association.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results